THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
As people age, the risk of fracturing a bone – whether it’s a hip, a wrist, vertebrae, an ankle or toe, climbs steadily. For women and men who live after a cancer diagnosis, the risk of breaking bone ...
Osteoporosis and osteoporosis-related fracture are important considerations in older patients; however, osteoporosis in men is often underrecognized and undertreated. At the time of this study, it was ...
Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...
PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced results from a 7-year, single-arm, open-label extension of the 3-year randomized, double-blind, placebo-controlled, multi-center ...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...
Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity score-matched analysis, adherence to ...
THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback